← Leaderboards
Manish Aghi
University Of California, San Francisco
$7,964,418
Attributed
$7,964,418
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $861.3K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,964,418 · 4
By mechanism
R01$7,048,668 · 3
K02$915,750 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Matthew F Krummel$32,506,768
- Qing Li$7,606,806
- Aparna Bala Sundaram$3,043,645
- Hyunil Jo$2,065,344
Others in their field
Top investigators on “Glioblastoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$50,454,235
- John H Sampson · Duke University$34,869,540
- Walter John Curran · Thomas Jefferson University$27,327,059
- Jann N Sarkaria · Mayo Clinic Coll Of Medicine, Rochester$23,947,143
- Jeremy N Rich · University Of Pittsburgh At Pittsburgh$21,935,828
- Maciej S Lesniak · Northwestern University$18,837,339
Research focus
GlioblastomaCellsTumorMalignant NeoplasmsIn VivoTumor MicroenvironmentMediatingMalignant Neoplasm Of BrainNeoplastic CellTumor GrowthResistanceBaseOutcome ForecastIntegrinsEffective TherapyLigandsTechnologyBrain NeoplasmsClustered Regularly Interspaced Short Palindromic RepeatsLibrariesRecurrenceDiagnosisInnovationMouse Model
Grant awards (25)
Retroviral RLI immunomodulatory gene therapy for glioblastoma$403,750
R01 · FY2025 · NS · contact PI
Retroviral RLI immunomodulatory gene therapy for glioblastoma$391,638
R01 · FY2024 · NS · contact PI
Retroviral RLI immunomodulatory gene therapy for glioblastoma$403,750
R01 · FY2023 · NS · contact PI
Retroviral RLI/4-1 BBL and RLI/FLT3L Combination Immunomodulatory Gene Therapy for Glioblastoma$95,027
R01 · FY2023 · NS · contact PI
Retroviral RLI immunomodulatory gene therapy for glioblastoma$403,750
R01 · FY2022 · NS · contact PI
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems$395,717
R01 · FY2022 · CA · contact PI
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems$414,033
R01 · FY2021 · CA · contact PI
Tumor cell and microenvironment changes causing antiangiogenic therapy resistance$352,024
R01 · FY2021 · NS · contact PI
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems$423,892
R01 · FY2020 · CA · contact PI
Tumor cell and microenvironment changes causing antiangiogenic therapy resistance$351,943
R01 · FY2020 · NS · contact PI
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems$85,485
R01 · FY2020 · CA · contact PI
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems$417,577
R01 · FY2019 · CA · contact PI
Tumor cell and microenvironment changes causing antiangiogenic therapy resistance$379,887
R01 · FY2019 · NS · contact PI
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems$454,956
R01 · FY2018 · CA · contact PI
Tumor cell and microenvironment changes causing antiangiogenic therapy resistance$348,933
R01 · FY2018 · NS · contact PI
Tumor cell and microenvironment changes causing antiangiogenic therapy resistance$346,719
R01 · FY2017 · NS · contact PI
Tumor cell and microenvironment changes causing antiangiogenic therapy resistance$346,719
R01 · FY2016 · NS · contact PI
Tumor cell and microenvironment changes causing antiangiogenic therapy resistance$346,719
R01 · FY2015 · NS · contact PI
Tumor cell and microenvironment changes causing antiangiogenic therapy resistance$342,347
R01 · FY2014 · NS · contact PI
Tumor cell and microenvironment changes causing antiangiogenic therapy resistance$343,802
R01 · FY2013 · NS · contact PI
Characterizing and Targeting Tumoral Factors Recruiting Perivascular Progenitors$190,656
K02 · FY2013 · NS · contact PI
Characterizing and Targeting Tumoral Factors Recruiting Perivascular Progenitors$190,656
K02 · FY2012 · NS · contact PI
Characterizing and Targeting Tumoral Factors Recruiting Perivascular Progenitors$178,146
K02 · FY2011 · NS · contact PI
Characterizing and Targeting Tumoral Factors Recruiting Perivascular Progenitors$178,146
K02 · FY2010 · NS · contact PI
Characterizing and Targeting Tumoral Factors Recruiting Perivascular Progenitors$178,146
K02 · FY2009 · NS · contact PI